Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury’s Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

The final judgment, if upheld, would entitle Sight Sciences to ongoing royalties at a rate of 10% of revenue for each Hydrus sold for the period after entry of the final judgment through the ...
WFXG

Sight Sciences’ Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and ...

Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care ...
Seeking Alpha

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

A Meta-Analysis of 22 Studies, and Data from the IRIS ® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication ...
ETF Daily News

Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Rating of “Hold” by Brokerages

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) has received a consensus rating of “Hold” from the seven brokerages that are covering the company, MarketBeat Ratings reports. Five equities ...
Nasdaq

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% ...

Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...